Document is current
Any future updates will be listed below
-
Authors
Kim, Minjeong
Song, Eunice S. https://orcid.org/0000-0003-0642-7083
Chen, Joseph C.
Chatterjee, Sumanta
Sun, Yehui https://orcid.org/0000-0003-0215-6095
Lee, Sang M. https://orcid.org/0000-0001-7658-6229
Wu, Shiying https://orcid.org/0000-0002-6902-9544
Patel, Priyanka
Tian, Zeru
Kantor, Ariel
Wustman, Brandon A.
Lockhart, David J.
Siegwart, Daniel J. https://orcid.org/0000-0003-3823-1931
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA142543)
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 9 April 2025
First Online: 2 June 2025
Competing interests
: A provisional patent application covering compositions, methods and uses for targeting cystic fibrosis and related disorders has been filed by UT Southwestern. D.J.S. is a co-founder and member of the scientific advisory board of ReCode Therapeutics, which has licensed intellectual property from UT Southwestern. D.J.S. discloses financial interests in ReCode Therapeutics, Signify Bio, Jumble Therapeutics and Tome Biosciences. J.C.C., A.K., B.A.W. and D.J.L. are employees of ReCode Therapeutics and have stock options in the company. All other authors declare that they have no competing interests.
